Form 4: Cullinan Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Thomas Ebeling, a director at Cullinan Therapeutics, exercised stock options at prices of $4.3 and $12.73 on May 23, 2024.
Summary
- On May 23, 2024, Thomas Ebeling, a director of Cullinan Therapeutics, Inc., executed transactions involving the company's common stock.
- Ebeling exercised stock options to acquire 84,224 shares at $4.30 per share and 16,475 shares at $12.73 per share.
- Following these transactions, Ebeling directly owns 168,203 shares of Cullinan Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock option exercises, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the number of shares outstanding.
Key Dates
| Date | Description |
|---|---|
| August 16, 2018 | 25% of the shares vested. |
| June 08, 2023 | Date exercisable for some stock options. |
| May 23, 2024 | Date of transaction: Ebeling exercised stock options. |
| May 23, 2024 | Date of Form 4 filing. |
| June 21, 2032 | Expiration date for some stock options. |
| October 28, 2030 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.